Show: October 7, 2012:
- Why is workplace-related asthma on the rise?
- Are toothache’s linked to bad grades?
- Should routine ovarian cancer screenings end?
- How does your state fare on the Women’s Health Report Card?
- Will promising treatments soon be available to breast cancer patients newly diagnosed with aggressiv
- What do smart sutures mean for the future of wound care?
- What is the microbiome and how does it help us?
- View all topics for the week
Will promising treatments soon be available to breast cancer patients newly diagnosed with aggressiv
Interview: Kathy Miller, M.D.
The Food and Drug Administration has announced a decision to allow drug companies to test new cancer drugs on women with newly diagnosed, early-stage but aggressive breast cancer. This is a change from the former policy, which dictated that the drug had to first be tested on patients with more advanced disease before being made available to patients early in their diagnosis. This move is a significant departure in which patients can participate in drug trials, testing the new drugs when they may have the strongest probability of success. Kathy Miller, M.D., discusses the potential benefits and risks of this policy change as well as whether she believes the FDA has taken a more aggressive approach to clinical research.